BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1437922)

  • 1. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
    Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
    Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An audit of the management of malignant hypercalcaemia.
    Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
    Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
    Coukell AJ; Markham A
    Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
    McIntyre HD; Cameron DP; Urquhart SM; Davies WE
    Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
    Wimalawansa SJ
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
    Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
    Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of pamidronate in patients with bone metastases.
    Leyvraz S; Hess U; Flesch G; Bauer J; Hauffe S; Ford JM; Burckhardt P
    J Natl Cancer Inst; 1992 May; 84(10):788-92. PubMed ID: 1573666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
    Gurney H; Kefford R; Stuart-Harris R
    Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose of bisphosphonate for hypercalcaemia of malignancy.
    Morton AR; Friefeld J; Halperin F
    Lancet; 1990 Jun; 335(8703):1469-70. PubMed ID: 1972245
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
    Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
    Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A; Graves L
    South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.